Q&A Genmab 2019-03-04

	4/3 17:14 af Jan Van de Winkel	In general, we estimate that per patient costs for clinical trials amount to about 1 million DKK per patient..
	4/3 17:14 af Jan Van de Winkel	On our top ten projects we will spend approximately 1.3 bn DKK in 2019. These will be split between our top 2 projects of about 800 m DKK and the next 8 at about 500 m DKK. So on the early stage projects, we will spending about 60 m DKK per project...
	4/3 17:11 af troldmanden	Could you try and shed some light on the clinical cost What ballpark figure can do you calculate per person for the early phase 1/2 trials and later phase 2 and 3 trials. And as a bonus question what amount do you believe J&J have used so fare on Dare?
	4/3 17:11 af Jan Van de Winkel	The numbers we are referring to were solely for MM. Currently there are also studies ongoing in Amyloidosis, NKTCL lymphoma and ALL so there could be further upside is such studies would read out positively..
	4/3 17:10 af Darvin	Genmab says the potential for Darzalex is greater than $ 10 billion. Can you tell us whether Genmab finds this likely within the current indications, including Amyloidosis, or whether you are calculating the use of Darzalex in other cancers?
	4/3 17:10 af Jan Van de Winkel	The covering analysts for Genmab currently estimate peak sales north of 9.5 bn USD for MM..
	4/3 17:09 af Jan Van de Winkel	I can confirm that the numbers from the latest survey among European and US physicians on the use of DARZALEX in multiple lines of therapy of MM north of 10 bn USD. As this is a model, we do not want to provide further colour...
	4/3 17:07 af Budweis	Congratulations with the 20th anniversary! What a journey. Last week you participated in an video interview with the danish newspaper Børsen. Can you tell us a little more about the consultant report that have been made calculating the potential dara sale north of 10bn$. What is the peaksale estimate and how is it split between US and ROW?
	4/3 17:07 af Jan Van de Winkel	Finally, we expect to file INDs/CTAs for three more proprietary programs in 2019..
	4/3 17:07 af Jan Van de Winkel	...
	4/3 17:07 af Jan Van de Winkel	In the second half of this year we expect meaningful clinical data for all of our four proprietary clinical programs
	4/3 17:06 af Jan Van de Winkel	For this year we expect a speedy approval of DARZALEX in frontline MM based on the MAIA data and we look forward to other data with Daratumumab, the GRIFFIN study, the CANDOR study and of course the full data of the COLUMBA study, where we hit both of the primary endpoints last week...
	4/3 17:04 af Jan Van de Winkel	Revenue 4.6 bn; OPEX 2.6 bn leading to a new record operating income of DKK 2 bn. Revenue driven by continued success of DARZALEX...
	4/3 17:03 af Helge Larsen/PI-redaktør	The investors and stock market appreciates Genmab's guidance for 2019. What do you expect in key figures and important events this year?
	4/3 17:02 af Jan Van de Winkel	Finally, we introduced an exciting new technology, HexElect, and a strategic collaboration with Immatics..
	4/3 17:02 af Jan Van de Winkel	We progressed the Phase I/II study of enapotamab vedotin in solid tumors into the expansion phase, and treated the first patients in the first-in-human studies of HexaBody-DR5/DR5 in solid tumors and DuoBody-CD3xCD20 in B-cell malignancies…
	4/3 17:02 af Jan Van de Winkel	Our collaboration with Seattle Genetics continues to be fruitful, with four new studies started or announced last year. One of these studies, called innovaTV 204 is a potential Phase II registration study in recurrent or metastatic cervical cancer…
	4/3 17:01 af Jan Van de Winkel	DARZALEX became a double blockbuster, with net sales by Janssen exceeding the USD 2 billion sales mark during 2018, triggering a USD 75 million milestone payment to Genmab…
	4/3 17:01 af Jan Van de Winkel	Reported positive topline results from the MAIA and CASSIOPEIA studies…
	4/3 17:01 af Jan Van de Winkel	Split dosing regimen approved in Europe and in the US [early 2019]…
	4/3 17:01 af Jan Van de Winkel	Key 2018 achievements: Darzalex approved in US & Europe in combination with bortezomib, melphalan and prednisone (VMP) in frontline multiple myeloma (MM)…
	4/3 17:01 af Jan Van de Winkel	Operating result DKK 1,380 mio, up DKK 36 mio or 3% and net result DKK 1,472 mio, up DKK 368 mio or 33%...
	4/3 17:00 af Jan Van de Winkel	Expenses DKK 1,645 mio up DKK 624 mio or 61% (or DKK 456 mio. / 49% after reimbursement from partners)…
	4/3 17:00 af Jan Van de Winkel	Revenue DKK 3,025 mio up DKK 660 mio. or 28%...

	4/3 17:00 af Jan Van de Winkel	Financial highlights: For the sixth year in a row we are profitable, with our Revenue, Operating Result and Net Result in 2018 at the highest level in the history of Genmab…
	4/3 17:00 af Helge Larsen/PI-redaktør	First of all let me congratulate on the great results for 2018 . Can you give us a short-term update on key figures and important events?
	4/3 16:58 af Helge Larsen/PI-redaktør	Good afternoon Jan van de Winkel and Peter Eatwell. Welcome to Q&A here on ProInvestor.com. We are very happy to have you ba ck here and ready to answer questions from our investors.
	4/3 16:57 af Helge Larsen/PI-redaktør	Great.
	4/3 16:57 af Jan Van de Winkel	Hello all. We are ready for your questions. Jan van de Winkel and David Eatwell here..
	4/3 15:57 af Helge Larsen/PI-redaktør	This session starts at 16 o'clock.